IDNA
iShares Genomics Immunology and Healthcare ETF
Set alert
42.76 USD -0.23 -0.54%
42.30 Day range 43.75
24.62 52-week range 43.47
- YTD
- +63.27%
- 1 year
- +69.62%
- Open
- 42.89
- Prev close
- 42.99
- Mkt cap
- 201.57M
- Vol
- 291.18K
- Avg vol
- 140.84K
- EPS
- 1.56
- P/E
- 27.48
- Div yield
- 0.00%
More statistics
- Low
- 42.30
- High
- 43.75
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 24.11
- 200-d avg
- 23.98
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 24.77
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 24.11
- 200-day average
- 23.98
About iShares Genomics Immunology and Healthcare ETF
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.
News
- Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
- Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
- Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
- IDNA: 3 Catalysts To Watch Closely
- Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
- iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Up 428.3% in January
- Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
- Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
- IDNA: The Cutting Edge Of Medical Science Is A Risky Investment
- Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?
Your note
Sign in to keep a note on IDNA — it syncs with the Stock Master app.